menu
    • menu
    [{"orgOrder":0,"company":"Avexegen Therapeutics","sponsor":"National Institutes of Health","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"U.S.A","productType":"Peptide","year":"2021","type":"Funding","leadProduct":"Neuregulin-4-based therapy","moa":"","graph1":"Gastroenterology","graph2":"Undisclosed","graph3":"Avexegen Therapeutics","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Avexegen Therapeutics \/ NIH","highestDevelopmentStatusID":"1","companyTruncated":"Avexegen Therapeutics \/ NIH"}]

    Find Clinical Drug Pipeline Developments & Deals by Avexegen Therapeutics

    Menu

    Avexegen Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Avexegen Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed

                            Avexegen Therapeutics

                            U.S.A arrow
                            Pharma, Lab & Chemical Expo
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Neuregulin-4-based therapy

                            Therapeutic Area : Gastroenterology

                            Study Phase : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease

                            Details : Avexegen will use the NIH funds to develop an orally efficacious, NRG-4-based drug product with localized action in the gut and a superior safety profile.

                            Brand Name : Undisclosed

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            February 15, 2021

                            Lead Product(s) : Neuregulin-4-based therapy

                            Therapeutic Area : Gastroenterology

                            Highest Development Status : Undisclosed

                            Sponsor : National Institutes of Health

                            Deal Size : $3.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth